Ovid Therapeutics

Ovid Therapeutics, Inc. is a biopharmaceutical company, engaged in the development of medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.

NEW YORK, June  19, 2020  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to OV101 (gaboxadol) for the treatment of Angelman syndrome. OV101 is believed to be the only delta (δ)-selective GABAA receptor agonist in development and is currently being evaluated in the Company’s pivotal Phase 3 NEPTUNE trial in Angelman syndrome, with topline results expected in the fourth quarter of 2020. The FDA has previously granted Orphan Drug and Fast Track designations for OV101 for the treatment of Angelman syndrome.

Ovid Therapeutics Receives FDA Rare Pediatric Disease Designation for OV101 for the Treatment of Angelman Syndrome

The small-cap biopharma got a nod from an analyst.

Why Ovid Therapeutics Stock Is Soaring Today

Identiv

Plug Power

Vonage Hlds

When choosing cheap stocks to invest in you don't always have to sacrifice quality. Here are four high-quality companies that are affordable.

4 Cheap Stocks to Invest in Today

NEW YORK, June  11, 2020  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced a strategic research collaboration with Columbia University Irving Medical Center researchers (“Columbia”) to advance genetic based therapies for a range of rare neurological conditions, complementary to Ovid’s current pipeline. This collaboration provides Ovid with the potential to expand its future drug development portfolio and impact individuals living with rare genetic neurological conditions.

Ovid Therapeutics Announces Strategic Research Collaboration Focused on Accelerating the Development of New Treatments for Rare Neurological Diseases

B2Gold

Constellium NV Class A

Dynavax Technologies

LiveXLive Media

Sequans Communications

X4 Pharmaceuticals Inc

For new investors, stocks under $10 offer both learning opportunities and huge upside potential. Here are 10 names to buy cheap.

10 Cheap Stocks to Buy Under $10

NEW YORK, June  08, 2020  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced multiple presentations across its rare neurological disease platform are available on the 2020 American Academy of Neurology (AAN) Science Highlights platform. The presentations were originally slated for discussion at the AAN 72nd Annual Meeting scheduled for April 25-May 1, which was cancelled due to the COVID-19 pandemic. The abstracts were also published in the online supplement to Neurology.

Ovid Therapeutics Announces Multiple Presentations on the 2020 American Academy of Neurology Science Highlights Platform

Ovid Advances Fragile X Syndrome Drug Forward; Multiple Catalysts Still Expected In 2020

NEW YORK, May  07, 2020  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced positive topline results from the signal-finding Phase 2 ROCKET trial of OV101 (gaboxadol), a novel delta (δ)-selective GABAA receptor agonist, in males with Fragile X syndrome. Fragile X syndrome is the most common inherited form of intellectual disability and autism, with no approved therapies. In addition, Ovid today provided preliminary findings from SKYROCKET, a non-drug interventional study in Fragile X syndrome.

Ovid Therapeutics Announces Positive Topline Results from the Phase 2 ROCKET Trial of OV101 for the Treatment of Fragile X Syndrome

Ardmore Shipping

CorMedix

Arcimoto

Top Ranked Momentum Stocks to Buy for April 22nd

Gilead Sciences

Intercept Pharma

Intra-Cellular Therapies

Karyopharm Therapeutics

The coronavirus pandemic has cast the spotlight on the world of biotechnology stocks as researchers search for not only a vaccine, but for additional drugs that can help in the treatment of the virus.

RBC Has 5 Biotech Stocks Rated Outperform With Up to 100% Upside Potential

NEW YORK, March  11, 2020  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided an overview of the Company’s recent progress and key clinical readouts anticipated in 2020.

Ovid Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update for 2020

Cidara Therapeutics

Callon Petroleum

Kadmon Hlds

NexTier Oilfield Solutions Inc

QEP Resources

No matter what, investors are always after returns. These six cheap stocks can make those returns a reality in 2020.

6 Cheap Stocks to Buy Under $7

Iteris

Matinas BioPharma Hlds

OrganiGram Holdings Inc.

Snapping up strong buy stocks with great long-term growth prospects doesn’t have to cost you your entire savings.
The post 5 Strong Buy Stocks Under $5 With Massive Upside Potential appeared first on InvestorPlace.

5 Strong Buy Stocks Under $5 With Massive Upside Potential

Seasoned CNS and Rare Disease Commercial Executive Further Strengthens Executive Management Team

Ovid Therapeutics Appoints Jason Tardio as Chief Commercial Officer

AMC Entertainment

ANGI Homeservices

Glu Mobile

Meet Group

Target Hospitality Corp

Boingo Wireless

These stocks come from a variety of industries, but all have positive catalysts in their futures. Buy these cheap stocks now while you can.

10 Cheap Stocks to Buy Under $10.

As of late, it has definitely been a great time to be an investor Ovid Therapeutics.

Will Ovid Therapeutics Continue to Surge Higher?

NEW YORK, Oct.  04, 2019  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare neurological diseases, today announced the pricing of two concurrent but separate underwritten public offerings (together, the “Offerings”) of (i) 9,000,000 shares of its common stock and (ii) 4,000 shares of its non-voting Series A Convertible Preferred Stock (the “Series A preferred stock”). The public offering price of each share of common stock is $2.50 and the public offering price of each share of Series A preferred stock is $2,500  (each share of Series A preferred stock is convertible into 1,000 shares of common stock). In addition, Ovid Therapeutics has granted the underwriters a 30-day option to purchase additional shares of common stock of up to 15% of the aggregate number of shares offered in the common stock offering. The Offerings are expected to close on October 8, 2019, subject to customary closing conditions.

Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock

NEW YORK, Oct.  03, 2019  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare neurological diseases, today announced that it intends to offer and sell shares of its common stock and Series A convertible preferred stock (the “Series A preferred stock”) in two concurrent but separate underwritten public offerings. Neither of the proposed common stock offering or the Series A preferred stock offering (together, the “Offerings”) are contingent upon the consummation of the other. The Offerings are subject to market and other conditions, and there can be no assurance as to whether or when the Offerings may be completed, or the actual size or terms of the Offerings.

Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock

Sustained and Progressively-Improving Median Seizure Frequency Reduction Reaching 84-90% with Prolonged Treatment of Soticlestat in this Difficult-to-Treat Patient Population

Ovid Therapeutics Announces Positive Initial Data from Ongoing ENDYMION Open-Label Extension Trial of Soticlestat in People with Rare Epilepsies

NEW YORK, Sept.  09, 2019  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Jeremey Levin, DPhil, MB, BChir, Chairman and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 21st Annual Global Investment Conference on Tuesday, September 10, 2019 at 9:30 a.m. EDT. In addition, Dr. Levin will give a keynote address entitled “The State of the Biotechnology Sector Going into an Election Year” on Tuesday, September 10, at 1:00 p.m. EDT. The conference will be held at the Lotte New York Palace Hotel in New York City.

Ovid Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference

NEW YORK, Sept.  03, 2019  (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced its participation in two upcoming investor conferences in September:

Ovid Therapeutics Announces Participation in Two Upcoming Investor Conferences

Amarin Corporation Plc

Ocular Therapeutix

Despite this truncated trading week, Tuesday was a breakout day for a few biotech companies.

Tuesday’s Biggest Biotech Movers (July 2)

Shares have lost roughly 87% since IPO and fallen by more than 80% since my last update article.

Ovid Therapeutics: Multiple Ways To Win In This Beaten-Down Biotech

Ovid Therapeutics Inc. shares have been on a steady downtrend since Aug. 6, 2018, when it released topline data from a Phase 2 study dubbed STARS that evaluated its OV101 for treating a genetic disorder known as Angelman syndrome.

Ovid Therapeutics Rallies On Rare Genetic Disorder Drug Data

News for Ovid Therapeutics Stock (OVID)